Limiting duration of treatment with checkpoint inhibitors: the data

(4:11)

Immunotherapy Side Effects: What Patients Need to Know with Dr. Jeffery Weber

(30:53)

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber

(3:40)

Dr. Jeffrey Weber, MD, PhD at Laura \u0026 Isaac Perlmutter Cancer Center and Academy of Immuno-Oncology

(6:16)

Three Cameras, same photo hide

(5:55)

Victorian Psycho, encuentro con Virginia Feito

(58:57)

Violeta Bozanic - Interview with Jeffrey Weber in LA ( \

(4:22)

Five profitable improvements to the Robert Lichello AIM Investing Method

(13:25)

Conversation with Annie Jacobsen, Nuclear War: A Scenario

(58:31)

Jeffrey Weber sings \

(1:28)

The Future of Melanoma: What to Anticipate in 2023 with Neoadjuvant and Adjuvant Pembrolizumab

(47:59)

Les 25 plus grosses transactions au 21e siècle... j'ai oublié la première (réaction)

(22:41)

Haynes N (2014): Cancer microenvironment and immunity - lessons for immunotherapy

(54:39)

January 9th Anchor Gathering with Susan Crenshaw, Tiffany Washington, and Jeffrey Weber

(50:10)

Cancer Revealed: How the Immune System Sees and Destroys Tumors, with Jeffrey Weber

(1:2:36)

4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma

(5:44)

Jeffrey Weber - \

(3:15)

How to manage chronic non-cutaneous immune-related toxicites

(5:25)

3-year update from the KEYNOTE-942 trial: mRNA-4157 (V940) + pembrolizumab in resected melanoma

(1:5)

Tocilizumab with ipilimumab and nivolumab in unresectable melanoma

(1:)

Adjuvant nivolumab in patents with high-risk resected melanoma

(2:22)

Clinical trials investigating the treatment of melanoma

(1:13)

Metastatic Melanoma: The Immunotherapy Approach

(7:)

Future Directions for Targeted Therapy - BRAF, NRAS, and more

(39:1econd)

The future of immune checkpoint inhibition in melanoma

(58)

Melanoma: Mechanisms of Resistance to Therapy

(8:42)

Honoring the Life and Legacy of Dr. Jeffrey S. Weber

(4:15)

Optimal Treatment of Metastatic Melanoma at Progression

(9:7)